Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04218565
Other study ID # GOL-BDU-PUMCH
Secondary ID
Status Terminated
Phase Phase 2
First received
Last updated
Start date February 15, 2020
Est. completion date December 15, 2022

Study information

Verified date April 2023
Source Peking Union Medical College Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this single-center prospective study is to evaluate the efficacy and safety of Golimumab (GOL), fully humanized anti-tumor necrosis factor (TNF)-α monoclonal antibody, in the treatment of refractory Uveitis of Behçet's disease (BDU), to verify its effects on decreasing the dose of cortical steroids, and to determine whether it can reduce BDU recurrence.


Description:

Uveitis of Behçet's disease (BDU) is the most common form of ocular manifestations, which is also the leading cause of irreversible visual impairment. The aim of the study is to improve the treatment strategy of the disease as well as to reduce blindness. Monoclonal anti-TNF antibodies were recommended in 2018 recommendations for treating eye involvement affecting the posterior segment (level of evidence: IIA; strength of recommendation: B), Infliximab was mentioned for the treatment of initial or recurrent episode of acute sight-threatening uveitis. Golimumab (GOL)is a fully-humanized anti-TNF-α monoclonal antibody, retrospective study on non-infectious uveitis and BDU has obtained promising results. This single-center prospective study is to evaluate the efficacy and safety of GOL in the treatment of refractory BDU, to verify its effects on tapering the dose of corticosteroids, and to determine whether it can reduce BDU recurrence. We aim to enroll nine refractory BDU patients with acute onset posterior uveitis, with difficulty tapering corticosteroids while being treated with at least one of the commonly used immunosuppressants. All participants will receive GOL monthly for six months, oral immunosuppressants will remain unchanged. During follow-up, intraocular inflammation status, BCVA, as well as extraocular manifestations, will be recorded. The primary endpoints are the efficacy of the first dose of GOL, and the recurrence of uveitis after 12 months of treatment. Secondary endpoints other than intraocular inflammation will be achieved on each follow-up visit, as the quality of life improvements, side effects, recurrence of uveitis, and corticosteroids-tapering effects. On statistical analysis, the self-control treatment efficiency and recurrence rate difference will be determined using T-test of paired samples at a significance level of 0.05(2-sided). To ensure the interest of the participants, our study has been reviewed by the ethics committee, and drug clinical research liability insurance was prepared.


Recruitment information / eligibility

Status Terminated
Enrollment 1
Est. completion date December 15, 2022
Est. primary completion date December 15, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - All participants fulfill the proposed International Criteria for BD, either ISG (International Study Group) criteria(1990) or ICBD(International Conference on Behcet's Disease) criteria(2013). - All participants present with refractory BDU, acute onset uveitis, either posterior segment involvement or panuveitis, with difficulty tapering corticosteroids while being treated with at least one of the commonly used immunosuppressants, without severe extraocular manifestations. Exclusion Criteria: - Patients with impaired hepatic and renal function, other severe ocular diseases, active tuberculosis, viral hepatitis, malignancy, pregnancy, congestive heart failure, or had biologics treatment within three months will be excluded.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Golimumab (GOL)
Patients with refractory BD associated uveitis will receive Golimumab therapy, the efficacy and corticosteroids-sparing effects will be evaluated.

Locations

Country Name City State
China Peking Union Medical College Hospital Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Wenjie Zheng

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Efficacy of Golimumab on BD Uveitis Efficacy of Golimumab based on Behçet's disease ocular attack score 24 (BOS24) four weeks
Primary Efficacy of Golimumab on BD Uveitis Efficacy of Golimumab based on Best corrected visual acuity(BCVA) four weeks
Primary Efficacy of Golimumab on BD Uveitis Efficacy of Golimumab based on Optical Coherence tomography(OCT)). four weeks
Primary Difference of recurrence rate before and after intervention Difference of recurrence rate of uveitis before and after 12 months of GOL treatment 12 months
Secondary Intraocular inflammation evaluation BOS24 index Visual acuity, anterior chamber cells, vitreous opacities, retinal inflammation, macular thickness, etc. each follow-up visit / every four weeks, up to six months
Secondary Corticosteroid-tapering effects Corticosteroid will be tapered to minimum dose(Prednisone 5-10mg/d) within four months during the course of GOL treatment. six months
Secondary Changes of uveitis recurrence Changes of recurrence rate before and after six months of GOL treatment. six months
Secondary Severity of uveitis on recurrence Differences of severity of recurrence before and after treatment, measured by BOS24. six months
Secondary Severity of uveitis on recurrence Differences of severity of recurrence before and after treatment, measured by , BCVA. six months
Secondary Severity of uveitis on recurrence Differences of severity of recurrence before and after treatment, measured by OCT. six months
Secondary Impact on quality of life Record quality of life on questionnaire, BehÇet's disease current activity form 2006(BDCAF2006). each follow-up visit / every four weeks, up to six months
Secondary Impact on quality of life Record quality of life on questionnaire, short from Health Survey(SF-36). each follow-up visit / every four weeks, up to six months
Secondary Side effects of treatment Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 six months
See also
  Status Clinical Trial Phase
Recruiting NCT04101604 - Biomarkers of Common Eye Diseases
Active, not recruiting NCT04704609 - Imaging Quantification of Inflammation (IQI)
Completed NCT03173144 - Chronic Inflammatory Disease, Lifestyle and Treatment Response
Withdrawn NCT01280669 - Intravitreal Sirolimus as Therapeutic Approach to Uveitis Phase 2
Terminated NCT02907814 - Measurement of Anterior Chamber Cell Grading Using Ocular Coherence Tomography N/A
Active, not recruiting NCT02252328 - Use of Simvastatin as a Steroid Sparing Agent for Uveitis Patients Phase 2/Phase 3
Completed NCT04183387 - Simvastatin in Uveitis Phase 2
Completed NCT01983488 - Clinical Outcome in Uveitis
Withdrawn NCT00499551 - A Phase I/IIa Study for the Treatment of Uveitis With Iontophoresis Phase 1/Phase 2
Completed NCT00476593 - Retinal OCT and (mfERG) Related to Age, Sex, and the Use of Anti-inflammatory Medications N/A
Terminated NCT00114062 - Study to Treat Uveitis Associated Macular Edema Phase 2
Completed NCT00132691 - Multicenter Uveitis Steroid Treatment (MUST) Trial Phase 4
Completed NCT00001867 - Effect of Pregnancy on Uveitis N/A
Completed NCT00379275 - Eye and Immunogenetic Features of Sarcoidosis N/A
Active, not recruiting NCT03828019 - Adalimumab vs. Conventional Immunosuppression for Uveitis Trial Phase 3
Terminated NCT01939691 - Macular Edema Nepafenac vs. Difluprednate Uveitis Trial Phase 4
Active, not recruiting NCT03889860 - Objective Choroidal Thickness Measurements in Uveitis
Completed NCT00070759 - Daclizumab to Treat Non-Infectious Sight-Threatening Uveitis Phase 2
Recruiting NCT05486468 - The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment Phase 3
Active, not recruiting NCT05385757 - UNICORNS: Uveitis in Childhood Prospective National Cohort Study